Development of a selective and sensitive polymerase chain reaction assay for the detection of Mycoplasma pirum

Abstract A new assay using the polymerase chain reaction to amplify a 173-nucleotide DNA fragment within the 16S ribosomal RNA gene of Mycoplasma pirum has been developed. The assay selectively amplified DNA from all strains of M. pirum tested with a high level of sensitivity, even in a context of human DNA. DNA from other mollicute species, including those closely related to M. pirum , from bacteria phylogenetically close to mollicutes ( Clostridium innocuum, C. ramosum and Bacillus subtilis ), from Escherichia coli and from human peripheral blood mononuclear cells, did not produce the amplified DNA product specific for M. pirum .     

The enhancement of the human immunoglobulin G Fc fragment-binding activity of Mycoplasma salivarium cells by trypsin treatment is ascribed to the binding of trypsin to the Fc fragment

Abstract Human immunoglobulin G Fc fragment-binding activity of Mycoplasma salivarium cells was remarkably enhanced by trypsin treatment of the cells. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis profile of proteins of the cells treated wtrypsin was the same as that of the cells treated with pronase, although pronase treatment had been shown to reduce the activity in our previous study (FEMS Microbiol. Lett. 123, 305–310, 1994). This contradiction was clarified by the finding that trypsin bound the Fc fragment more strongly than the cells, and a small amount of trypsin remained in the cells treated with trypsin and washed well. On the basis of these results, it was concluded that the enhancement of cell activity by trypsin treatment was ascribed to binding of the Fc fragment to trypsin remaining in the trypsin-treated cells.     

Plasmid transformation and replica filter plating of Acholeplasma laidlawii

The restriction deficient mutant 8195 of Acholeplasma laidlawii strain JA1 was transformed by the promiscuous streptococcal plasmid vector pNZ18 at a frequency of 4 x 10(-4)/cfu. The plasmid was maintained without structural rearrangements but was lost in the absence of a selection pressure, i.e. kanamycin or neomycin. Transformed primary colonies were easily recognized due to a different colony morphology. Replica filter plating, previously not obtained with mycoplasmas, was achieved using pNZ18 as a marker by incubating the replica filters with the cell side down on the new agar plates. These findings should greatly facilitate the genetic and functional analysis of A. laidlawii.     

猪肺炎支原体检测技术研究进展

猪支原体肺炎是由猪肺炎支原体(Mycoplasma hyopneumoniae,Mhp)引起的一种存在于世界各地的严重危害养猪业的疾病,严重影响饲料报酬,造成巨大的经济损失。准确、敏感、快速的Mhp检测方法有助于了解Mhp在猪群的流行情况,进而采取相应的预防、治疗和综合防控措施。对国内外Mhp病原学、分子生物学和免疫学检测方法进行了综述,为科技工作者全面了解Mhp检测方法提供参考资料。     

小儿肺热咳喘口服液联合阿奇霉素对肺炎支原体肺炎患儿肺功能和炎性因子的影响

目的:探讨小儿肺热咳喘口服液联合阿奇霉素对肺炎支原体肺炎患儿肺功能和炎性因子的影响。方法:选取2016年1月～2017年12月期间我院收治的175例肺炎支原体肺炎患儿,根据随机数字表法将其分为对照组(n=87,阿奇霉素治疗)和研究组(n=88,小儿肺热咳喘口服液联合阿奇霉素治疗),比较两组患儿临床疗效、临床症状消失时间、肺功能指标[第1s用力呼气容积(FEV1)、用力肺活量(FVC)、FEV1/FVC]、炎性因子指标[肿瘤坏死因子-α(TNF-α)、白介素-6(IL-6)、C反应蛋白(CRP)],记录两组患儿不良反应发生情况。结果:研究组患儿治疗后临床总有效率为94.32%(83/88),高于对照组患儿的80.46%(70/87)(P0.05)。研究组患儿咳嗽、发热、湿啰音、哮鸣音的消失时间均短于对照组(P0.05)。两组患儿治疗后FEV1、FVC、FEV1/FVC均升高,且研究组高于对照组(P0.05)。两组患儿治疗后IL-6、CRP、TNF-α水平均降低,且研究组低于对照组(P0.05)。两组患儿不良反应发生率对比无统计学差异(P0.05)。结论:小儿肺热咳喘口服液联合阿奇霉素治疗肺炎支原体肺炎患儿的疗效优于单用阿奇霉素,且可有效改善患儿肺功能和炎性因子水平,快速缓解临床症状,促进患儿恢复。     

高渗盐水雾化吸入治疗儿童支原体肺炎继发哮喘发作及对其T淋巴细胞亚群及Th1、Th2型细胞因子的影响

目的:探讨高渗盐水雾化吸入治疗儿童支原体肺炎继发哮喘发作的临床疗效及对其T淋巴细胞亚群及Th1、Th2型细胞因子的影响。方法:选取我院2015年6月到2017年6月间收治的支原体肺炎继发哮喘发作患儿100例为研究对象。随机分为对照组和观察组,各50例。两组均给予吸氧、抗生素、维持酸碱度、电解质平衡及相应症状等对症治疗,对照组给予生理盐水结合沙丁胺醇进行雾化治疗,观察组采用3%高渗盐水结合沙丁胺醇进行雾化治疗,比较两组患儿发热、咳嗽、肺内啰音、咽部肿痒等症状消失时间及临床疗效;比较两组治疗前后CD3~+、CD4~+、CD8~+、CD4~+/CD8~+、IFN-γ及IL-4水平情况。结果:观察组患儿发热、咳嗽、肺内啰音、咽部肿痒等临床症状消失时间显著早于对照组,差异有统计学意义(P0.05);观察组总有效率96.00%明显高于对照组80.00%,差异有统计学意义(P0.05);两组患儿治疗前CD3~+、CD4~+、CD8~+、CD4~+/CD8~+、IFN-γ及IL-4水平比较差异无统计学意义(P0.05);治疗后CD3~+、CD4~+、CD4~+/CD8~+及IFN-γ水平均明显升高,CD8~+及IL-4水平明显降低,差异均有统计学意义(均P0.05);且观察组治疗后CD3~+、CD4~+、CD4~+/CD8~+及IFN-γ水平均明显高于对照组,CD8~+及IL-4水平明显低于对照组,差异均有统计学意义(均P0.05)。结论:高渗盐水雾化吸入能够显著改善支原体肺炎继发哮喘发作患儿临床症状,提高CD3~+、CD4~+、CD4~+/CD8~+及Th1水平,抑制CD8~+及Th2水平,临床疗效确切,值得临床推广应用。     

阿奇霉素治疗小儿支原体肺炎的效果观察和安全性分析

目的观察大环内酯类抗生素阿奇霉素治疗小儿支原体肺炎的临床疗效,并对用药安全性进行评价。方法选择我院2012年6月至2014年10月呼吸科收治的96例小儿支原体肺炎患者,随机平均分为观察组和对照组。观察组给予阿奇霉素治疗,对照组给予红霉素治疗,观察两组的临床疗效和不良反应。结果观察组患者治愈37例,显效8例,无效3例,总有效率为93.75%;对照组治愈30例,显效9例,无效9例,总有效率为81.25%,治疗组疗效优于对照组,差异有统计学意义(P0.05)。治疗组患者平均退热、止咳、平喘、肺部啰音消失时间均短于对照组,平均住院时间和住院花费均少于对照组,差异有统计学意义(P0.05)。两组均偶见局部皮疹、注射部分疼痛等轻度不良反应,差异无统计学意义;观察组无胃肠道反应,对照组有4例胃肠道反应。结论阿奇霉素治疗小儿支原体肺炎能有效改善临床症状,较红霉素能提高治疗效果,缩短病程,且无严重不良反应,安全可靠,值得推广应用。